Overview

  • US healthcare group posts preliminary Q2 revenue of approximately $19.4 mln, up 31.5% year-over-year

  • Company repurchased 3.64 mln shares for about $700,000 under $5 mln buyback program

Outlook

  • Company did not provide specific guidance for future quarters or full-year results

Result Drivers

  • BUSINESS EXECUTION - CEO attributed record revenue to ongoing execution across the company's platform

Company press release:

Key Details

Metric

Q2 Revenue

Beat/Miss

Actual

$19.40 mln

Consensus Estimate

Analyst Coverage

  • Wall Street's median 12-month price target for Cosmos Health Inc is $4.50, about 1,567.3% above its July 6 closing price of $0.27

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact .